3Huang ZF, Huang F. Update the management of spondyloarthritis in Asian countries. Curr Rheumatol Rev, 2012, 8:39-44. 被引量：1
4Luosujarvi RA, Husman TM, Seuri M, et al. Joint symptoms and diseases associated with moisture damage in a health center. Clin Rheumatol,2003 ,22 :381-385. 被引量：1
5Tamer IH, Muller-Ladner U, Uhlemann C, et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol, 2009,28 : 397 -402. 被引量：1
6Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis,2012,71:809-816. 被引量：1
7Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour neerosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology ( Oxford ) , 2006, 45 : 1223- 1229. 被引量：1
8Rosenbaum JT, Davey MP. Time for a gut check: evidence for the hypothesis that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome. Arthritis Rheum,2011,63:3195-3198. 被引量：1
9Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med, 1994,180:2359-2364. 被引量：1
10Fielder M, Pirt SJ, Tarpey I, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett,1995,369:243- 248. 被引量：1
3Dougados M, B6hier JM, Jolchine I,et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum, 2001,44 : 180-185. 被引量：1
4Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis,2011,70:896-904. 被引量：1
5Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford) ,2010,49:536-541. 被引量：1
6Wanders A, Heijde Dv, Landew6 R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical triM. Arthritis Rheum ,2005,52 : 1756-1765. 被引量：1
7Straube S, Trainer MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol,2009,9:41. 被引量：1
8Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults : results of a US consensus panel of experts. Arch Intern Med, 2003,163:2716-2724. 被引量：1
9Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/ epidemiological studies in axial spondyloarthritis. Ann Rheum Dis,2011,70:249-251. 被引量：1
10] Ramiro S, Radner I-I, van der Heijde DM, et al. Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review. J Rheumato! Suppl,2012 ,90 :47-55. 被引量：1
